Clinical Trial

Aldebaran

Phase 2 study
Testing the safety and tolerability of Alogobat, administered as once-daily oral tablet.

Alogabat is a GABA-modulator which aims to restore GABA functioning which would improve symptoms and potentially aid brain development.

Roche

Participant Requirements

Below is a preliminary list of inclusion criteria.
See the full list of eligibility criteria on the clinical trials website.

  • Clinical diagnosis of deletion genotype of Angelman syndrome
  • Between 5 and 17 years old
  • Able to undergo blood draws, ECG and EEG assessments

Locations

Boston, MA
Boston Children’s Hospital
Contact: batsheva.friedman@childrens.harvard.edu

Chicago, IL
Rush Medical Center
Contact: Sara_A_Sandoval@rush.edu

New York, NY
Columbia University Medical Center

Carrboro, NC
Carolina Institute for Development Disabilities University of North Carolina/School of Medicine
Contact: victoria_banks@neurology.unc.edu

Bedford Park, Australia, South Australia
Flinders Medical Centre Recruiting

Marseille, France
Hopital la Timone Enfants; Service de Pediatrie et Neurologie Pediatrique

Paris, France
Groupe Hospitalier Necker Enfants Malades

Roma, Lazio, Italy
Ospedale Pediatrico Bambino Gesù; Dip. Neuroscienze e Neuroriabilitazione

Genova, Liguria, Italy
IRCCS Istituto G. Gaslini; UOC Neurologia Pediatrica e Malattie Muscolari

Sabadell, Barcelona, Spain
Corporacio Sanitaria Parc Tauli

More Information and Screening Enrollment

Find more information on the Roche website.

More details on clinicaltrials.gov

Questions about this study and enrollment interest can be directed to:
888-662-6728 (US and Canada) or global-roche-genentech-trials@gene.com

Reference Study ID Number: BP41315